Video

Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Author(s):

Aileen I. Fernandez, PhD

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Aileen I. Fernandez, PhD, postdoctoral fellow, Yale School of Medicine, discusses the utility of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer.

Trastuzumab deruxtecan targets HER2 and has demonstrated efficacy in patients who have low levels of HER2 expression, Fernandez says. Trastuzumab (Herceptin) has utility in patients with high levels of HER2 expression, Fernandez explains. However, if patients have immunohistochemistry 0 or 1+ disease, they won’t respond to trastuzumab. 

Trastuzumab deruxtecan is an antibody-drug conjugate comprised of an anti-HER2 antibody, a cleavable linker, and a topoisomerase inhibitor, Fernandez continues. If trastuzumab deruxtecan identifies any level of HER2 expression, it is then able to latch onto the cell and deliver its cytotoxic payload, Fernandez says. Then, it goes back into the bloodstream targeting the neighboring cells that do not have HER2 expression, which is why it has activity in HER2-low disease, Fernandez concludes

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Chief Translational Research Officer, Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
December 9th 2022

Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

Aarti Bhatia, MD, associate professor of medicine at Yale School of Medicine and medical oncologist at Smilow Cancer Hospital at Yale, New Haven, Connecticut.
November 30th 2022

Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

Melinda Irwin, PhD, MPH
April 6th 2022

Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

Alessandro Santin, MD
February 23rd 2022

Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

Natalia Neparidze, MD, of Yale Cancer Center
February 17th 2022

Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers